Connect Biopharma Holdings is back in focus after analysts refreshed their price targets, with fair value moving from US$5.88 to US$6.00 in the latest models. The shift follows new Street research that weighs the mixed Phase 2 Seabreeze STAT trial readout, updated Phase III timelines, and a balance of optimism around the asthma pipeline against execution and clinical risk. Read on to see how these revised targets fit into the evolving Connect Biopharma Holdings story and what to watch as the...
Detailed price information for Helus Pharma Inc (HELP-Q) from The Globe and Mail including charting and trades.
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Detailed price information for Connect Biopharma Holdings Ltd ADR (CNTB-Q) from The Globe and Mail including charting and trades.
U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
2026-09-30. The following slide deck was published by Connect Biopharma Holdings Limited in conjunction with this event.
Connect Biopharma reports positive Phase 2 results for rademikibart, showing an 81% reduction in COPD treatment failure and high safety.
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The market value of
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) – – Rademikibart significantly reduced the rate of new moderate to severe COPD exacerbations through one month by 85% (p=0.030) – – Rademikibart significantly reduced the rate of hospitalizations or emergency department visits for new acute COPD exacerbations by 100% (p=0.0137) – – Rademikibart was well tolerated in COPD patients experiencing an acute exacerbation with a low
Connect Biopharma Holdings Limited (NASDAQ:CNTB) reported mixed preliminary results on September 15 from its Phase 2 Seabreeze STAT asthma study. Rademikibart produced a numerical 66% reduction in treatment failure over 28 days versus placebo, but the primary endpoint missed statistical significance, with p=0.153. Connect Biopharma Holdings Limited (NASDAQ:CNTB) also reported a lung-function benefit on a […]
Connect Biopharma Holdings (CNTB) has an average rating of buy and mean price target of $6.52, accor
Detailed price information for Connect Biopharma Holdings Ltd ADR (CNTB-Q) from The Globe and Mail including charting and trades.
Connect Biopharma reported a statistically significant improvement in lung function in its Phase 2 Seabreeze STAT asthma trial, while a 66% reduction in treatment failures did not reach statistical significance. Key Investor TakeawaysConnect Biopharma (NASDAQ:CNTB) said rademikibart produced a statistically significant 130 mL placebo-adjusted improvement in post-bronchodilator FEV1 at Day 7, with a p-value of 0.
– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to placebo – – Rademikibart was well tolerated in asthma patients experiencing an acute exacerbation with a low incidence of adverse events– – Data from Seabreeze STAT COPD study of rademikibart will be available later this month after which Connect plans to engage with the U.S. Food and
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 11:30 a.m. ET. The live webcast of the presentation may be accessed v
Detailed price information for Connect Biopharma Holdings Ltd ADR (CNTB-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.